Medtronic has announced a series of regulatory and access milestones. The company received FDA clearance for its MiniMed 780G insulin pump to be used with ultra rapid-acting insulins Fiasp and Lyumjev. This update allows insulin delivery to more closely mirror the body’s natural response around meals, supporting tighter glucose control and greater flexibility for users.

In addition, Medtronic secured Medicare coverage for the MiniMed 780G when used with the Instinct continuous glucose monitor (CGM) made by Abbott, broadening access for older adults and others covered under Medicare. The FDA also cleared the MiniMed 780G and Instinct sensor combination for people with insulin-requiring type 2 diabetes, expanding the system’s indicated population beyond type 1 diabetes.

Looking ahead, Medtronic is continuing to invest in product innovation with the development of two new insulin pumps: the MiniMed Flex, a tubed pump, and the MiniMed Fit, a patch pump.